



Correction: Photobiomodulation: lasers vs. light emitting diodes?

Cite this: *Photochem. Photobiol. Sci.*, 2019, **18**, 259

Vladimir Heiskanen^a and Michael R. Hamblin^{*b,c,d}

DOI: 10.1039/c8pp90049c
rsc.li/pps

Correction for 'Photobiomodulation: lasers vs. light emitting diodes?' by Vladimir Heiskanen and Michael R. Hamblin, *Photochem. Photobiol. Sci.*, 2018, **17**, 1003–1017.

The Conflicts of Interest statement should be corrected to include a list of potential conflicts.

Dr Hamblin is on the following Scientific Advisory Boards: Transdermal Cap Inc, Cleveland, OH; BeWell Global Inc, Wan Chai, Hong Kong; Hologenix Inc, Santa Monica, CA; LumiThera Inc, Poulsbo, WA; Vielight, Toronto, Canada; Bright Photomedicine, Sao Paulo, Brazil; Quantum Dynamics LLC, Cambridge, MA; Global Photon Inc, Bee Cave, TX; Medical Coherence, Boston MA; NeuroThera, Newark DE; JOOVV Inc, Minneapolis-St Paul MN; Illumiheal & Petthera, Shoreline, WA; MB Lasertherapy, Houston, TX.

Dr Hamblin has been a consultant for USHIO Corp, Japan; Merck KGaA, Darmstadt, Germany; Philips Electronics Nederland B.V.; Johnson & Johnson Inc, Philadelphia, PA; AIRx Medical, Pleasanton CA; FIR Industries, Inc. Ramsey, NJ; UVLRx Therapeutics, Oldsmar, FL; Ultralux UV Inc, Lansing MI; Photothera Inc, Carlsbad, CA.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^aOral and Maxillofacial Diseases, University of Helsinki, Finland

^bWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA

^cDepartment of Dermatology, Harvard Medical School, Boston, MA 02115, USA

^dHarvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA. E-mail: hamblin@helix.mgh.harvard.edu

